Vinai Gondi
Expertise in
34
conditions

Dr. Vinai Gondi

Radiation Oncology
4405 Weaver Pkwy, 
Waterman, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
18 Years of Experience
Expertise in
34
conditions
4405 Weaver Pkwy, 
Waterman, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vinai Gondi is a Radiation Oncologist in Waterman, Illinois. Dr. Gondi has been practicing medicine for over 18 years is highly rated in 34 conditions, according to our data. His top areas of expertise are Brain Tumor, Astrocytoma, Glioblastoma, and Glioma.

His clinical research consists of co-authoring 101 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Columbia University Vagelos College Of Physicians And Surgeons, 2007
Residency
University of Wisconsin Hospitals and Clinics
Specialties
Radiation Oncology
Licenses
Radiology in IL
Board Certifications
American Board Of Radiology - Radiation Oncology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Medicine Kishwaukee Hospital
Northwestern Medicine Mchenry
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

4405 Weaver Pkwy, Waterman, IL 60555

Additional Areas of Focus

Dr. Gondi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Gamma Knife Radiosurgery

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Enrollment Status: Recruiting
Publish Date: June 11, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Memantine
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: June 06, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Radiation, Drug, Biological, Other
Study Phase: Phase 2
View 10 Less Clinical Trials

101 Total Publications

Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Matthew M. Harkenrider
Radiation Oncology
Expertise in
23
conditions
Dr. Matthew M. Harkenrider
Radiation Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (11.2 mi)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Harkenrider is a Radiation Oncologist in Maywood, Illinois. Dr. Harkenrider is highly rated in 23 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Lung Cancer, Small Cell Lung Cancer (SCLC), Cervical Cancer, and Prostatectomy. Dr. Harkenrider is currently accepting new patients.

Expertise in
10
conditions
Dr. Stanley L. Liauw
Radiation Oncology
Expertise in
10
conditions
Dr. Stanley L. Liauw
Radiation Oncology

University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.3 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stanley Liauw is a Radiation Oncologist in Chicago, Illinois. Dr. Liauw is highly rated in 10 conditions, according to our data. His top areas of expertise are Prostate Cancer, Anal Cancer, Familial Prostate Cancer, Prostatectomy, and Orchiectomy. Dr. Liauw is currently accepting new patients.

Expertise in
46
conditions
Dr. Edward Melian
Radiation Oncology
Expertise in
46
conditions
Dr. Edward Melian
Radiation Oncology
2160 S First Ave, (maguire Center, Rm. 2944), 
Maywood, IL 
 (11.3 mi)
708-216-2575
Languages Spoken:
English
See accepted insurances

Edward Melian is a Radiation Oncologist in Maywood, Illinois. Dr. Melian is highly rated in 46 conditions, according to our data. His top areas of expertise are Meningioma, Radiation Induced Meningioma, Glomus Tympanum Tumor, and Glomus Jugulare Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gondi's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 12 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile